Nevro Corp. Price, Consensus and EPS Surprise Nevro Corp. Price, Consensus and EPS Surprise In the quarter under review, Nevro’s gross profit declined 19.1% year over year to $65.1 million.
Nevro also offers minimally invasive treatment options for patients suffering from chronic sacroiliac (SI) joint pain. SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy ...
REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Tuesday reported a loss of $53.1 million in its fourth quarter. On a per-share basis, the Redwood City ...
Nevro also offers minimally invasive treatment options for patients suffering from chronic sacroiliac (SI) joint pain. SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy ...
As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor is the company holding an earnings conference call ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback